Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) CEO Grant Pickering sold 15,000 shares of the stock in a transaction on Monday, March 25th. The shares were sold at an average price of $66.93, for a total value of $1,003,950.00. Following the completion of the sale, the chief executive officer now owns 477,847 shares of the company’s stock, valued at approximately $31,982,299.71. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Grant Pickering also recently made the following trade(s):
- On Friday, March 1st, Grant Pickering sold 2,616 shares of Vaxcyte stock. The stock was sold at an average price of $73.70, for a total transaction of $192,799.20.
- On Thursday, February 1st, Grant Pickering sold 2,616 shares of Vaxcyte stock. The shares were sold at an average price of $73.91, for a total transaction of $193,348.56.
- On Monday, January 29th, Grant Pickering sold 30,000 shares of Vaxcyte stock. The stock was sold at an average price of $66.03, for a total value of $1,980,900.00.
- On Tuesday, January 23rd, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $63.92, for a total value of $958,800.00.
- On Tuesday, January 2nd, Grant Pickering sold 2,616 shares of Vaxcyte stock. The stock was sold at an average price of $63.89, for a total value of $167,136.24.
Vaxcyte Price Performance
Shares of NASDAQ:PCVX opened at $68.50 on Thursday. The company’s 50-day moving average price is $71.06 and its two-hundred day moving average price is $59.49. Vaxcyte, Inc. has a 12 month low of $34.11 and a 12 month high of $82.04.
Institutional Trading of Vaxcyte
Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in Vaxcyte by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 8,452,371 shares of the company’s stock valued at $530,809,000 after acquiring an additional 168,125 shares during the period. RA Capital Management L.P. boosted its stake in shares of Vaxcyte by 8.2% during the 2nd quarter. RA Capital Management L.P. now owns 7,891,254 shares of the company’s stock worth $394,089,000 after buying an additional 600,000 shares during the last quarter. BlackRock Inc. grew its stake in Vaxcyte by 39.0% in the second quarter. BlackRock Inc. now owns 7,065,088 shares of the company’s stock valued at $352,830,000 after purchasing an additional 1,983,223 shares in the last quarter. Wellington Management Group LLP raised its position in Vaxcyte by 3.8% during the third quarter. Wellington Management Group LLP now owns 4,598,712 shares of the company’s stock worth $234,442,000 after acquiring an additional 167,501 shares in the last quarter. Finally, Capital Research Global Investors grew its position in shares of Vaxcyte by 2.3% in the 4th quarter. Capital Research Global Investors now owns 3,440,107 shares of the company’s stock valued at $216,039,000 after acquiring an additional 75,980 shares during the period. 96.78% of the stock is owned by institutional investors.
Analysts Set New Price Targets
PCVX has been the subject of a number of recent analyst reports. Bank of America upped their price target on shares of Vaxcyte from $67.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, January 2nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research report on Friday, January 12th. Needham & Company LLC increased their target price on shares of Vaxcyte from $73.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, February 28th. Finally, Mizuho began coverage on shares of Vaxcyte in a report on Thursday, December 7th. They set a “buy” rating and a $69.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $78.50.
View Our Latest Stock Analysis on Vaxcyte
About Vaxcyte
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Featured Stories
- Five stocks we like better than Vaxcyte
- High Flyers: 3 Natural Gas Stocks for March 2022
- Bitcoin Depot Falls Into Value Territory With Expansion Underway
- Want to Profit on the Downtrend? Downtrends, Explained.
- 7 Stocks That Will Drive the Weight Loss Drugs Market
- ESG Stocks, What Investors Should Know
- Cintas or UniFirst: Investors Win Either Way
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.